Related Experiment Videos
Anti-Sc1 in pregnancy.
T Kaye1, E M Williams, S F Garner
1South London Blood Transfusion Centre, England.
Transfusion
|June 1, 1990
Summary
This study tracked anti-Sc1 antibodies during pregnancy. Despite a positive direct antiglobulin test at birth, the infant showed no signs of hemolytic disease, indicating a favorable outcome.
Area of Science:
- Immunology
- Maternal-Fetal Medicine
Background:
- Detection of anti-Sc1 antibodies during pregnancy can pose a risk for hemolytic disease of the fetus and newborn (HDFN).
- Monitoring antibody levels and subclass is crucial for assessing potential fetal risk.
Observation:
- Anti-Sc1 antibodies, IgG3 subclass, were detected early in gestation.
- Antibody-dependent cellular cytotoxicity (ADCC) assay showed low initial fetal lysis (7%), suggesting low risk.
- Direct antiglobulin test was positive at birth, but the infant had normal hemoglobin and required no transfusion.
Findings:
- The anti-Sc1 antibody titer and IgG3 subclass remained stable throughout pregnancy.
- Postnatal ADCC assay showed increased lysis (44%), correlating with a higher antibody titer.
- The infant did not develop HDFN despite a positive direct antiglobulin test.
Implications:
- This case highlights the potential for a favorable fetal outcome even with detectable anti-Sc1 antibodies and a positive direct antiglobulin test.
- Antibody-dependent cellular cytotoxicity (ADCC) assay may provide valuable information in predicting fetal risk.
- Further research is needed to fully understand the predictive value of ADCC assays in managing Rh-sensitized pregnancies.